Cempra, Inc. (NASDAQ:CEMP) runs in leading trade, it an ascending 7.69% to traded at $2.80. CEMP attains analyst recommendation of 2.90 on scale of 1-5 with week’s performance of -52.54%. Cempra Inc. cratered Thursday, after the U.S. Food and Drug Administration said it cannot approve a pneumonia drug without additional safety data and improvements at a manufacturing facility. The stock is now sitting at its lowest level since the company went public in February 2012 at $6 a share. Trading volume of 20.8million shares was more than eight times the daily average.
Cempra said that FDA had sent it a so-called complete response letter regarding its new drug applications (NDAs) for solithromycin, a treatment for community-acquired bacterial pneumonia. The letter states that the FDA cannot approve the NDAs in their current form and that the company must provide additional safety data and resolve unspecified issues with its manufacturing facility.
To find out the technical position of CEMP, it holds price to book ratio of 0.70 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. CEMP is presenting price to cash flow of 0.56. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -15.80%, and looking further price to next year’s EPS is -7.10%. While take a short look on price to sales ratio, that was 8.78.
CEL-SCI Corporation (NYSE:CVM) [Trend Analysis] retains strong position in active trade, as shares scoring -10.28% to $0.07 in a active trade session, while looking at the shares volume, around 3.78 Million shares have changed hands in this session. . The firm has institutional ownership of 7.20%, while insider ownership included 11.10%. CVM attains analyst recommendation of 2.00 with week’s performance of -24.41%.
The co is presenting price to cash flow as 4.73. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower. The firm has price volatility of 23.61% for a week and 15.28% for a month. Its beta stands at -0.93 times. Narrow down four to firm performance, its weekly performance was -24.41% and monthly performance was -68.00%.